Revcovi (elapegademase-lvlr) Injection, 2.4mg/1.5mL (1.6 mg/mL), Single-Dose Vial, Rx Only, For Intramuscular Use Only, Mfd. by Chiesi USA, Inc., Cary, NC 27518, NDC 10122-502-01
Published September 9, 2026 · Recall initiated: August 19, 2026
Summary
FDA records drug Class III recall D-0838-2026, published September 9, 2026 and initiated August 19, 2026. Recalling firm: Chiesi USA, Inc.; Status: Ongoing; Reported quantity: 3,002 vials; Lot: Lot#: 1221973, Exp 3/24/2027. Class III means the product is not likely to cause adverse health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Stability Specifications: Out of specification stability result for the protein concentration profile.
What to do
Voluntary: Firm initiated · Letter
Get an email if REVCOVI has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- REVCOVI
- Manufacturer
- Chiesi USA, Inc.
- Distributor
- MO, TN
- Lot
- Lot#: 1221973, Exp 3/24/2027
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDA2% Chlorhexidine Gluconate* Cloth, Non-sterile, 6 Disposable cloths, Sage Products LLC, 3909 Three Oaks Road,September 9, 2026
- FDAPrasugrel Tablets, USP, 10mg, Rx only, 30 Tablets in each bottle, Manufactured for: Mylan PharmaceuticalsSeptember 9, 2026
- FDAtraZODone Hydrochloride Tablets, USP, 50 mg, Rx only, 100 Tablets, Manufactured in Croatia By: Pliva HrvatskaSeptember 9, 2026
- FDABuprenorphine Sublingual Tablets (C-III), 2 mg, 30 Tablets (3x10), Rx only, Distributed by: American HealthSeptember 9, 2026
- FDATrokendi XR, (topiramate) extended-release capsules, 50 mg, 30 Capsules, Rx only, Manufactured by: CatalentSeptember 9, 2026
- FDAPrasugrel HCI, Tablets, USP, 10mg, 30-count bottle, Rx only, Marketed by: GSMS, Incorporated, Camarillo, CASeptember 9, 2026
Questions about this recall
Was Revcovi (elapegademase-lvlr) Injection, 2.4mg/1.5mL (1.6 mg/mL), Single-Dose Vial, Rx Only, For Intramuscular Use Only, Mfd. by Chiesi USA, Inc., Cary, NC 27518, NDC 10122-502-01 recalled?
Yes. FDA published recall D-0838-2026 on September 9, 2026. Reported hazard: Failed Stability Specifications: Out of specification stability result for the protein concentration profile.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: REVCOVI.